<DOC>
	<DOCNO>NCT01593254</DOCNO>
	<brief_summary>The purpose study test hypothesis patient CML achieve optimal response 3 month treatment imatinib well response switch dasatinib compare stay original imatinib regimen .</brief_summary>
	<brief_title>Study Dasatinib v Imatinib Patients With Chronic Myeloid Leukemia ( CML ) Who Did Not Have Favorable Response Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Chronic Phase ( CP ) CML Ph+ patient complete hematologic response ( CHR ) one log BCRABL reduction ( BCRABL level &gt; 10 % IS ) 3 month imatinib 400mg treatment . ( Imatinib transient dose adjustment due Adverse Event ( AEs ) allow maximum 2 week interruption treatment imatinib ( cumulative ) within 3 month period randomization ) . Imatinib monotherapy must start within 6 month CPCML diagnosis ( Ph + /BCRABL detection ) Currently tolerate imatinib 400mg QD . Patients prior imatinib treatment interruption dose reduction require treatment 400 mg imatinib two week immediately prior randomization ensure tolerance imatinib Eastern CoOperative Group ( ECOG ) performance status = 0 2 Adequate renal function define serum creatinine ≤3 time institutional upper limit normal ( ULN ) Adequate hepatic function define : total bilirubin ≤2.0 time institutional ULN ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5 time institutional ULN Previous diagnosis accelerate phase blast crisis Subjects clonal evolution Ph+ cell observe ≥2 metaphase baseline bone marrow cytogenetic test , unless abnormality present diagnosis . Patients evidence clonal evolution , include patient whose cytogenetic testing fail bone marrow aspiration dry tap 3 month , eligible study Subjects less CHR 3 month imatinib treatment lose CHR initial achievement Documented T315I/A , F317L , V299L mutation ( already available require screening ) A serious uncontrolled medical disorder active infection would impair ability subject receive protocol therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>